Abstracts Archive - Page 770 of 2607 - ACR Meeting Abstracts

Abstract Number: 0973 • ACR Convergence 2021
Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants
MacIntosh Cornwell¹, Hanane EL Bannoudi², Elliot Luttrell-Williams¹, Khrystyna Myndzar¹, Alexis Engel³, Peter Izmirly⁴, H. Michael Belmont⁵, Robert Clancy⁶, Jeffrey Berger¹, Kelly Ruggles¹ and Jill Buyon⁶, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY
Background/Purpose: The clinical heterogeneity of SLE with its complex pathogenesis remains challenging as we strive to provide optimal management. The contribution of platelets to endovascular…
Abstract Number: 0974 • ACR Convergence 2021
Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis
Katelyn Baggett¹, Timothy Brandon¹, Rui Xiao², Zachary Valenzuela¹, Lisa Buckley³ and Pamela Weiss¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Vanderbilt Children's Hospital, Nashville, TN
Background/Purpose: Tumor necrosis factor inhibiting (TNFi) therapies are associated with new-onset psoriasis in children with inflammatory bowel disease (IBD) and juvenile idiopathic arthritis (JIA). We…
Abstract Number: 0975 • ACR Convergence 2021
Data-driven MRI Definitions for Active and Structural Sacroiliac Joint Lesions in Juvenile Spondyloarthritis Typical of Axial Disease
Pamela Weiss¹, Timothy Brandon¹, Amita Aggarwal², Ruben Burgos-Vargas³, Robert Colbert⁴, Gerd Horneff⁵, Rik Joos⁶, Ronald Laxer⁷, Kirsten Minden⁸, Angelo Ravelli⁹, Nicolino Ruperto¹⁰, Judith Smith¹¹, Matthew Stoll¹², Shirley Tse⁷, Filip Van den Bosch¹³, Robert Lambert¹⁴, David Biko¹⁵, Nancy Chauvin¹⁶, Michael Francavilla¹⁵, Jacob Jaremko¹⁴, Nele Herregods¹⁷, Ozgur Kasapcopur¹⁸, Mehmet YILDIZ¹⁹, Alison Hendry²⁰ and Walter Maksymowych²¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ³Department of Rheumatology, General Hospital of Mexico, Ciudad de Mxico, Mexico, ⁴NIH/NIAMS, Bethesda, MD, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Ghent University, Ghent, Belgium, ⁷SickKids, Toronto, ON, Canada, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Istituto Giannina Gaslini, Genoa, Italy, ¹⁰IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹¹University of Wisconsin, Madison, WI, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵University of Pennsylvania, Philadelphia, PA, ¹⁶Penn State Health, Hershey, PA, ¹⁷Universitair Ziekenhuis Ghent, Ghent, Belgium, ¹⁸Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ¹⁹Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ²⁰NZ Familial GI Cancer Service, Auckland, New Zealand, ²¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: Determining optimal cut-offs for active and structural imaging lesions of juvenile spondyloarthritis (JSpA) with axial disease is important for diagnosis, therapeutic management, and classification.…
Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…
Abstract Number: 0977 • ACR Convergence 2021
Enhancement of Patient and Clinician Partnerships in Juvenile Idiopathic Arthritis Management Using a Point-of-Care Dashboard: Development and Pilot Testing
Erica Lawson¹, Lisa Johnson², Jabeen Ahmad², Vincent Del Gaizo³, Brittany Donaldson⁴, Julie Eller⁵, Yukiko Kimura⁶, Cathy Knucken⁷, Tzielan Lee⁸, Corinne Pinter⁹, Doreen Tabussi¹⁰, Alysha Taxter¹¹ and Aricca Van Citters², ¹University of California San Francisco, San Francisco, CA, ²Dartmouth College, Lebanon, NH, ³Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁴Wake Forest University School of Medicine Brenner Children's, Winston Salem, NC, ⁵Arthritis Foundation, Washington, DC, ⁶Hackensack University Medical Center, New York, NY, ⁷Patient Partner, Byram, NJ, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹Patient Partner, Sugar Land, TX, ¹⁰Hackensack University Medical Center, Upper Saddle River, NJ, ¹¹Wake Forest Baptist Medical Center, Winston-Salem, NC
Background/Purpose: Health outcomes improve when people living with chronic conditions partner with their clinicians to coproduce care based on their values, preferences, goals, and the…
Abstract Number: 0978 • ACR Convergence 2021
Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
Amer Khojah¹, Gabrielle Morgan² and Lauren Pachman³, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Neopterin is a metabolic product of guanosine triphosphate, which is produced by macrophages upon stimulation with interferon-gamma from activated T helper cells. Despite the…
Abstract Number: 0979 • ACR Convergence 2021
Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations
Jonathan Li¹, Emily Mirizio¹, Katherine Buhler², May Choi³, Haiyan Hou², Giffin Werner¹, Anwesha Sanyal¹, Kaila Schollaert-Fitch¹, Marvin Fritzler² and Kathryn Torok¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Pediatric scleroderma encompasses juvenile onset localized scleroderma (jLS) and juvenile onset systemic sclerosis (jSSc), both of which present with varied cutaneous fibrosis and systemic…
Abstract Number: 0980 • ACR Convergence 2021
Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with paraoxonase, lactonase, and arylesterase activities.1 PON1 gene polymorphisms at the Q192R allele (rs662) have been associated…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 0982 • ACR Convergence 2021
B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach
Aurelie Najm¹, Shrutii Sarda², Michelle Toro³, Loni Pickle³, Stephanie Ostresh³, Fraser Morton⁴, Geoffrey Lowman³, Andrew Felton⁵ and Carl Goodyear⁴, ¹Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, South San Francisco-CA, United States, San Francisco, ³Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, Carlsbad, CA, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵VP, Platforms, Research & Applied, Specialty Diagnostics Group, South San Francisco, CA
Background/Purpose: The adaptive immune system plays a central role in Rheumatoid Arthritis (RA) pathogenesis. Moreover, the composition of the B cell repertoire and its perturbation…
Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Andrea Rubbert-Roth¹, Nicolas Vuilleumier², Burkhard Ludewig³, Kristin Schmiedeberg⁴, Yella Rottlaender⁴, Ian Pirker⁵ and Johannes VonKempis⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Departement Diagnostique, University of Geneva, Switzerland, Geneva, Switzerland, ³Institute of Immunobiology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁶Division of Rheumatology and Immunology, St. Gallen, Switzerland
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Kevin Sheng-Kai Ma, Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…
Abstract Number: 0985 • ACR Convergence 2021
Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
Sara McCoy¹, Miguel Woodham¹, Ian Saldanha², Esen Akpek³, VATINEE BUNYA⁴ and Alan Baer⁵, ¹University of Wisconsin, Madison, WI, ²Brown University School of Public Health, Providence, RI, ³Wilmer Eye Institute, JHU, Baltimore, MD, ⁴University of Pennsylvania, Penn Valley, PA, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjӧgren’s syndrome (SS) patients have lower quality of life driven by symptoms of pain, depression and fatigue. These symptoms often do not respond to…
Abstract Number: 0986 • ACR Convergence 2021
Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
Thomas Dörner¹, Simon J Bowman², Robert Fox³, Xavier Mariette⁴, Athena Papas⁵, Thomas Grader-Beck⁶, Ben A Fisher², Filipe Barcelos⁷, Salvatore De Vita⁸, Hendrik Schulze-Koops⁹, Robert Moots¹⁰, Guido Junge¹¹, Janice Woznicki¹², Monika Sopala¹¹, Wen-Lin Luo¹² and Wolfgang Hueber¹¹, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Scripps Memorial Hospital and Research Institute, San Diego, CA, ⁴Université Paris- Saclay, Rheumatology, Paris, France, ⁵Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁶Johns Hopkins University, Baltimore, MD, ⁷Instituto Português de Reumatologia, Lisbon, Portugal, ⁸Division of Rheumatology, DAME, University Hospital of Udine, Udine, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹⁰Academic Rheumatology Department, Aintree University Hospital, Liverpool, United Kingdom, ¹¹Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterized by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell…
Abstract Number: 0987 • ACR Convergence 2021
Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial
Elena Pontarini¹, Farzana Chowdhury¹, Elisabetta Sciacca¹, Sofia Grigoriadou¹, Felice Rivellese¹, Davide Lucchesi¹, Katriona Goldmann¹, Liliane Fossati-Jimack¹, Paul Emery², Wan-Fai NG³, Nurhan Sutcliffe⁴, Colin C Everett⁵, Catherine Fernandez⁵, Anwar Tappuni⁶, Myles Lewis¹, Costantino Pitzalis⁷, Simon J Bowman⁸ and Michele Bombardieri¹, ¹Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ³Translational and Clinical Research Institute, Newcastle University,, Newcastle, United Kingdom, ⁴Royal London Hospital, Bart’s Health NHS Trust, London, United Kingdom, ⁵Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁶Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Queen Mary University of London, London, United Kingdom, ⁷Queen Mary University of London, London, United Kingdom, ⁸Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: The pathogenic role of B-cells in primary Sjögren’s Syndrome (pSS) is well established and B cell abnormalities are hallmarks of the disease. Because of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].